Share Price and Basic Stock Data
Last Updated: January 22, 2026, 8:33 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Global Longlife Hospital and Research Ltd operates within the Hospitals & Medical Services sector, focusing on healthcare delivery. The company’s reported revenue has shown a declining trend over recent years, with sales recorded at ₹32.44 Cr in March 2022, falling to ₹23.38 Cr in March 2023, and further decreasing to ₹13.46 Cr in March 2024. This decline in sales is concerning, particularly given the projected revenue of only ₹0.31 Cr for March 2025. Quarterly sales also reflected this downward trajectory, with a peak of ₹19.94 Cr in September 2021, decreasing to ₹11.70 Cr by March 2023, and a slight uptick to ₹12.33 Cr in September 2023. The company’s reliance on timely patient admissions and treatment services is evident, as operational disruptions may severely impact revenue. Historical data indicates that the hospital’s performance has been volatile, with significant fluctuations in both operational and financial metrics, which could deter potential investors in a sector that typically demands stability and consistent growth.
Profitability and Efficiency Metrics
Global Longlife Hospital’s profitability metrics have been under pressure, with a net profit of -₹2.36 Cr reported for the latest financial year. The company has experienced fluctuating operating profit margins (OPM), which stood at 25.59% in March 2022 but drastically declined to -1,335.48% in March 2025, indicating severe operational inefficiencies. The operating profit for March 2024 was recorded at -₹0.22 Cr, a stark contrast to the ₹8.30 Cr in March 2022. Moreover, the interest coverage ratio (ICR) of 3.10x suggests that while the company can meet its interest obligations, the financial health remains precarious. The cash conversion cycle (CCC) has been extended, standing at 376.77 days in March 2025, which is significantly higher than the typical sector range, indicating inefficiencies in managing receivables and payables. Furthermore, the return on equity (ROE) was reported at 17.7%, but this figure is tempered by the company’s negative net profit, raising concerns about sustainable profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Global Longlife Hospital reflects a noteworthy absence of borrowings, standing at ₹0.00 Cr, which is a positive indicator of financial stability. However, the total liabilities have fluctuated, recorded at ₹26.85 Cr in March 2025, down from ₹75.94 Cr in March 2023. The company’s reserves also saw a decline, reported at ₹14.97 Cr in September 2025, from a high of ₹53.79 Cr in March 2023. The price-to-book value (P/BV) ratio stood at 0.74x, suggesting that the stock may be undervalued compared to its book value. However, the asset turnover ratio of 0.01% indicates inefficiencies in utilizing assets to generate revenue. The current ratio is exceptionally high at 405.69x, suggesting an overliquid position, which is not typical for the sector and may indicate poor capital allocation. Overall, while the lack of debt is a strength, the declining reserves and asset turnover raise concerns about the company’s operational efficiency and long-term financial health.
Shareholding Pattern and Investor Confidence
As of September 2025, the shareholding pattern of Global Longlife Hospital indicates that promoters hold a significant 55.10% stake, reflecting a strong insider commitment to the company. The public shareholding stood at 44.91%, with a total of 915 shareholders. This distribution indicates a balanced ownership structure, which is often viewed positively by investors. However, the decline in the number of shareholders from 937 in December 2022 to 915 in September 2025 may signal waning investor confidence. The promoters have maintained their stake consistently, which may provide some reassurance to investors, but the lack of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) suggests limited external interest. This could be a red flag for potential investors, as institutional support is often seen as a vote of confidence in a company’s prospects. The overall stability in promoter holding, coupled with the declining public interest, could lead to increased volatility in the stock price.
Outlook, Risks, and Final Insight
Global Longlife Hospital faces several risks, primarily stemming from its declining revenue and profitability metrics. The significant drop in sales from ₹32.44 Cr in March 2022 to a projected ₹0.31 Cr in March 2025 raises serious concerns about its operational viability. Additionally, the high cash conversion cycle and negative operational profit margins indicate potential inefficiencies that could further exacerbate financial instability. On the other hand, the company’s debt-free status and substantial promoter holding provide a foundation for potential recovery. If the management can implement effective operational efficiencies and capitalize on its strong equity position, there may be opportunities for growth. However, without a clear strategy to improve revenue and restore investor confidence, the outlook remains precarious. Investors should closely monitor operational improvements and market conditions, as the situation could evolve positively or negatively depending on management’s responsiveness to these challenges.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.8 Cr. | 137 | 187/120 | 9.34 | 117 | 2.56 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 21.9 Cr. | 20.9 | 33.0/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.8 Cr. | 10.4 | 20.5/7.08 | 120 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 104 Cr. | 55.7 | 98.7/52.2 | 23.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.8 Cr. | 3.48 | 6.94/3.37 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 24,866.00 Cr | 662.81 | 87.45 | 93.18 | 0.35% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Global Longlife Hospital and Research Ltd
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.94 | 12.87 | 11.80 | 11.70 | 12.33 | 1.18 | 0.58 | 0.00 | 0.00 |
| Expenses | 13.18 | 11.61 | 10.03 | 9.44 | 9.62 | 4.20 | 4.39 | 0.35 | 0.60 |
| Operating Profit | 6.76 | 1.26 | 1.77 | 2.26 | 2.71 | -3.02 | -3.81 | -0.35 | -0.60 |
| OPM % | 33.90% | 9.79% | 15.00% | 19.32% | 21.98% | -255.93% | -656.90% | ||
| Other Income | 0.07 | 0.16 | 0.07 | 0.17 | 0.02 | 0.04 | 5.69 | -0.67 | 0.01 |
| Interest | 0.09 | 1.31 | 0.20 | 0.20 | 0.41 | 0.36 | 0.28 | 0.00 | 0.00 |
| Depreciation | 0.58 | 0.57 | 0.58 | 0.59 | 0.61 | 0.64 | 0.48 | 0.00 | 0.00 |
| Profit before tax | 6.16 | -0.46 | 1.06 | 1.64 | 1.71 | -3.98 | 1.12 | -1.02 | -0.59 |
| Tax % | 0.00% | -78.26% | 29.25% | 35.37% | 39.77% | -19.10% | -11.61% | 2.94% | 123.73% |
| Net Profit | 6.17 | -0.10 | 0.76 | 1.07 | 1.03 | -3.22 | 1.24 | -1.04 | -1.32 |
| EPS in Rs | 8.81 | -0.14 | 0.72 | 1.02 | 0.98 | -3.07 | 1.18 | -0.99 | -1.26 |
Last Updated: January 8, 2026, 6:24 am
Below is a detailed analysis of the quarterly data for Global Longlife Hospital and Research Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Sep 2025, the value is 0.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.35 Cr. (Mar 2025) to 0.60 Cr., marking an increase of 0.25 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.60 Cr.. The value appears to be declining and may need further review. It has decreased from -0.35 Cr. (Mar 2025) to -0.60 Cr., marking a decrease of 0.25 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Sep 2025, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from -0.67 Cr. (Mar 2025) to 0.01 Cr., marking an increase of 0.68 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.59 Cr.. The value appears strong and on an upward trend. It has increased from -1.02 Cr. (Mar 2025) to -0.59 Cr., marking an increase of 0.43 Cr..
- For Tax %, as of Sep 2025, the value is 123.73%. The value appears to be increasing, which may not be favorable. It has increased from 2.94% (Mar 2025) to 123.73%, marking an increase of 120.79%.
- For Net Profit, as of Sep 2025, the value is -1.32 Cr.. The value appears to be declining and may need further review. It has decreased from -1.04 Cr. (Mar 2025) to -1.32 Cr., marking a decrease of 0.28 Cr..
- For EPS in Rs, as of Sep 2025, the value is -1.26. The value appears to be declining and may need further review. It has decreased from -0.99 (Mar 2025) to -1.26, marking a decrease of 0.27.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:39 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 33.44 | 33.32 | 32.70 | 32.44 | 23.38 | 13.46 | 0.31 | 0.00 |
| Expenses | 26.61 | 29.88 | 27.26 | 24.14 | 19.30 | 13.68 | 4.45 | 0.95 |
| Operating Profit | 6.83 | 3.44 | 5.44 | 8.30 | 4.08 | -0.22 | -4.14 | -0.95 |
| OPM % | 20.42% | 10.32% | 16.64% | 25.59% | 17.45% | -1.63% | -1,335.48% | |
| Other Income | 0.08 | 0.03 | 0.06 | 0.17 | 0.24 | 0.00 | 5.02 | -0.66 |
| Interest | 2.07 | 2.41 | 2.44 | 1.62 | 0.45 | 0.80 | 0.30 | 0.00 |
| Depreciation | 2.15 | 2.13 | 1.31 | 1.14 | 1.17 | 1.25 | 0.48 | 0.00 |
| Profit before tax | 2.69 | -1.07 | 1.75 | 5.71 | 2.70 | -2.27 | 0.10 | -1.61 |
| Tax % | 49.07% | -18.69% | -16.57% | 37.30% | 32.59% | -3.52% | -100.00% | |
| Net Profit | 1.36 | -0.86 | 2.05 | 3.57 | 1.83 | -2.19 | 0.20 | -2.36 |
| EPS in Rs | 1.94 | -1.23 | 2.93 | 5.10 | 1.74 | -2.09 | 0.19 | -2.25 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -163.24% | 338.37% | 74.15% | -48.74% | -219.67% | 109.13% |
| Change in YoY Net Profit Growth (%) | 0.00% | 501.61% | -264.23% | -122.89% | -170.93% | 328.80% |
Global Longlife Hospital and Research Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -61% |
| 3 Years: | -79% |
| TTM: | -98% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -119% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -33% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | -4% |
| Last Year: | -18% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: January 7, 2026, 5:32 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.00 | 7.00 | 7.00 | 7.00 | 10.50 | 10.50 | 10.50 | 10.50 |
| Reserves | 5.35 | 4.49 | 6.68 | 9.96 | 53.79 | 15.43 | 16.29 | 14.97 |
| Borrowings | 27.18 | 23.51 | 17.04 | 8.69 | 9.29 | 12.74 | -0.00 | -0.00 |
| Other Liabilities | 3.77 | 6.92 | 6.06 | 8.33 | 2.36 | 3.07 | 0.06 | 0.01 |
| Total Liabilities | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 | 25.48 |
| Fixed Assets | 20.17 | 18.72 | 17.46 | 16.71 | 16.52 | 17.27 | -0.00 | -0.00 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | 1.03 | -0.00 | -0.00 | -0.00 |
| Investments | 0.10 | 0.10 | 0.47 | 0.10 | 0.10 | 0.03 | 0.03 | -0.00 |
| Other Assets | 23.03 | 23.10 | 18.85 | 17.17 | 58.29 | 24.44 | 26.82 | 25.48 |
| Total Assets | 43.30 | 41.92 | 36.78 | 33.98 | 75.94 | 41.74 | 26.85 | 25.48 |
Below is a detailed analysis of the balance sheet data for Global Longlife Hospital and Research Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.50 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.50 Cr..
- For Reserves, as of Sep 2025, the value is 14.97 Cr.. The value appears to be declining and may need further review. It has decreased from 16.29 Cr. (Mar 2025) to 14.97 Cr., marking a decrease of 1.32 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.01 Cr.. The value appears to be improving (decreasing). It has decreased from 0.06 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.05 Cr..
- For Total Liabilities, as of Sep 2025, the value is 25.48 Cr.. The value appears to be improving (decreasing). It has decreased from 26.85 Cr. (Mar 2025) to 25.48 Cr., marking a decrease of 1.37 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.03 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.03 Cr..
- For Other Assets, as of Sep 2025, the value is 25.48 Cr.. The value appears to be declining and may need further review. It has decreased from 26.82 Cr. (Mar 2025) to 25.48 Cr., marking a decrease of 1.34 Cr..
- For Total Assets, as of Sep 2025, the value is 25.48 Cr.. The value appears to be declining and may need further review. It has decreased from 26.85 Cr. (Mar 2025) to 25.48 Cr., marking a decrease of 1.37 Cr..
Notably, the Reserves (14.97 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -20.35 | -20.07 | -11.60 | -0.39 | -5.21 | -12.96 | -4.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 94.85 | 68.68 | 87.51 | 100.25 | 151.43 | 52.88 | 376.77 |
| Inventory Days | 169.49 | 157.97 | 34.46 | 88.98 | 69.12 | 131.64 | 0.00 |
| Days Payable | 229.91 | 391.69 | 138.68 | 432.74 | 110.43 | 765.90 | |
| Cash Conversion Cycle | 34.44 | -165.03 | -16.71 | -243.52 | 110.13 | -581.38 | 376.77 |
| Working Capital Days | 19.21 | 12.16 | 7.14 | -29.70 | 344.86 | -238.36 | 1,283.39 |
| ROCE % | 3.81% | 12.75% | 26.22% | 6.35% | -2.51% | -13.69% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.19 | -2.08 | 1.79 | 5.11 | 2.92 |
| Diluted EPS (Rs.) | 0.19 | -2.08 | 1.79 | 5.11 | 2.92 |
| Cash EPS (Rs.) | 0.64 | -0.89 | 2.85 | 6.74 | 5.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 25.51 | 24.70 | 61.23 | 24.23 | 19.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 25.51 | 24.70 | 61.23 | 24.23 | 19.54 |
| Revenue From Operations / Share (Rs.) | 0.54 | 12.87 | 22.38 | 46.88 | 46.72 |
| PBDIT / Share (Rs.) | 0.81 | -0.23 | 4.07 | 11.79 | 8.67 |
| PBIT / Share (Rs.) | 0.35 | -1.43 | 2.96 | 10.15 | 5.98 |
| PBT / Share (Rs.) | 0.09 | -2.16 | 2.58 | 8.16 | 2.51 |
| Net Profit / Share (Rs.) | 0.18 | -2.08 | 1.74 | 5.11 | 2.92 |
| PBDIT Margin (%) | 148.50 | -1.83 | 18.18 | 25.14 | 18.56 |
| PBIT Margin (%) | 65.02 | -11.08 | 13.22 | 21.66 | 12.81 |
| PBT Margin (%) | 17.18 | -16.76 | 11.52 | 17.40 | 5.37 |
| Net Profit Margin (%) | 34.41 | -16.19 | 7.77 | 10.89 | 6.25 |
| Return on Networth / Equity (%) | 0.74 | -8.43 | 2.84 | 21.06 | 14.96 |
| Return on Capital Employeed (%) | 1.40 | -5.09 | 4.56 | 35.19 | 15.94 |
| Return On Assets (%) | 0.74 | -5.24 | 2.40 | 10.51 | 5.56 |
| Long Term Debt / Equity (X) | 0.00 | 0.13 | 0.05 | 0.16 | 0.91 |
| Total Debt / Equity (X) | 0.00 | 0.49 | 0.14 | 0.51 | 0.91 |
| Asset Turnover Ratio (%) | 0.01 | 0.22 | 0.42 | 0.92 | 0.85 |
| Current Ratio (X) | 405.69 | 0.31 | 4.28 | 0.82 | 1.13 |
| Quick Ratio (X) | 405.69 | 0.28 | 4.17 | 0.75 | 1.06 |
| Inventory Turnover Ratio (X) | 2.64 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 3.10 | -0.32 | 10.67 | 5.90 | 2.50 |
| Interest Coverage Ratio (Post Tax) (X) | 1.72 | -1.85 | 5.56 | 3.55 | 1.84 |
| Enterprise Value (Cr.) | -1.58 | 53.35 | 52.71 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | -2.74 | 3.95 | 2.24 | 0.00 | 0.00 |
| EV / EBITDA (X) | -1.85 | -215.57 | 12.33 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 34.48 | 3.03 | 2.00 | 0.00 | 0.00 |
| Price / BV (X) | 0.74 | 1.58 | 0.73 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 34.54 | 3.03 | 2.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | -0.05 | 0.03 | 0.00 | 0.00 |
After reviewing the key financial ratios for Global Longlife Hospital and Research Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 5. It has increased from -2.08 (Mar 24) to 0.19, marking an increase of 2.27.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 3. It has increased from -0.89 (Mar 24) to 0.64, marking an increase of 1.53.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 25.51. It has increased from 24.70 (Mar 24) to 25.51, marking an increase of 0.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.54. It has decreased from 12.87 (Mar 24) to 0.54, marking a decrease of 12.33.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.81. This value is below the healthy minimum of 2. It has increased from -0.23 (Mar 24) to 0.81, marking an increase of 1.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.35. This value is within the healthy range. It has increased from -1.43 (Mar 24) to 0.35, marking an increase of 1.78.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from -2.16 (Mar 24) to 0.09, marking an increase of 2.25.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has increased from -2.08 (Mar 24) to 0.18, marking an increase of 2.26.
- For PBDIT Margin (%), as of Mar 25, the value is 148.50. This value is within the healthy range. It has increased from -1.83 (Mar 24) to 148.50, marking an increase of 150.33.
- For PBIT Margin (%), as of Mar 25, the value is 65.02. This value exceeds the healthy maximum of 20. It has increased from -11.08 (Mar 24) to 65.02, marking an increase of 76.10.
- For PBT Margin (%), as of Mar 25, the value is 17.18. This value is within the healthy range. It has increased from -16.76 (Mar 24) to 17.18, marking an increase of 33.94.
- For Net Profit Margin (%), as of Mar 25, the value is 34.41. This value exceeds the healthy maximum of 10. It has increased from -16.19 (Mar 24) to 34.41, marking an increase of 50.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 15. It has increased from -8.43 (Mar 24) to 0.74, marking an increase of 9.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 10. It has increased from -5.09 (Mar 24) to 1.40, marking an increase of 6.49.
- For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has increased from -5.24 (Mar 24) to 0.74, marking an increase of 5.98.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.00, marking a decrease of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.49 (Mar 24) to 0.00, marking a decrease of 0.49.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.01. It has decreased from 0.22 (Mar 24) to 0.01, marking a decrease of 0.21.
- For Current Ratio (X), as of Mar 25, the value is 405.69. This value exceeds the healthy maximum of 3. It has increased from 0.31 (Mar 24) to 405.69, marking an increase of 405.38.
- For Quick Ratio (X), as of Mar 25, the value is 405.69. This value exceeds the healthy maximum of 2. It has increased from 0.28 (Mar 24) to 405.69, marking an increase of 405.41.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 2.64, marking an increase of 2.64.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.10. This value is within the healthy range. It has increased from -0.32 (Mar 24) to 3.10, marking an increase of 3.42.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 3. It has increased from -1.85 (Mar 24) to 1.72, marking an increase of 3.57.
- For Enterprise Value (Cr.), as of Mar 25, the value is -1.58. It has decreased from 53.35 (Mar 24) to -1.58, marking a decrease of 54.93.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is -2.74. This value is below the healthy minimum of 1. It has decreased from 3.95 (Mar 24) to -2.74, marking a decrease of 6.69.
- For EV / EBITDA (X), as of Mar 25, the value is -1.85. This value is below the healthy minimum of 5. It has increased from -215.57 (Mar 24) to -1.85, marking an increase of 213.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 34.48. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.48, marking an increase of 31.45.
- For Price / BV (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. It has decreased from 1.58 (Mar 24) to 0.74, marking a decrease of 0.84.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 34.54. This value exceeds the healthy maximum of 3. It has increased from 3.03 (Mar 24) to 34.54, marking an increase of 31.51.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.01, marking an increase of 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Global Longlife Hospital and Research Ltd:
- Net Profit Margin: 34.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.4% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.74% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 405.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 87.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 34.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 703, Sankalp Square, 3B, Beside Taj Skyline, Sindhu Bhavan Road, Ahmedabad Gujarat 380059 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dhruv Jani | Managing Director |
| Ms. Hetal Thakkar | Executive Director & CFO |
| Mrs. Sucheta Jani | Non Executive Director |
| Mr. Manasvi Thapar | Independent Director |
| Mr. Sandeep Shah | Independent Director |
FAQ
What is the intrinsic value of Global Longlife Hospital and Research Ltd?
Global Longlife Hospital and Research Ltd's intrinsic value (as of 22 January 2026) is ₹34.44 which is 64.78% higher the current market price of ₹20.90, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹21.9 Cr. market cap, FY2025-2026 high/low of ₹33.0/15.5, reserves of ₹14.97 Cr, and liabilities of ₹25.48 Cr.
What is the Market Cap of Global Longlife Hospital and Research Ltd?
The Market Cap of Global Longlife Hospital and Research Ltd is 21.9 Cr..
What is the current Stock Price of Global Longlife Hospital and Research Ltd as on 22 January 2026?
The current stock price of Global Longlife Hospital and Research Ltd as on 22 January 2026 is ₹20.9.
What is the High / Low of Global Longlife Hospital and Research Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Global Longlife Hospital and Research Ltd stocks is ₹33.0/15.5.
What is the Stock P/E of Global Longlife Hospital and Research Ltd?
The Stock P/E of Global Longlife Hospital and Research Ltd is .
What is the Book Value of Global Longlife Hospital and Research Ltd?
The Book Value of Global Longlife Hospital and Research Ltd is 24.3.
What is the Dividend Yield of Global Longlife Hospital and Research Ltd?
The Dividend Yield of Global Longlife Hospital and Research Ltd is 0.00 %.
What is the ROCE of Global Longlife Hospital and Research Ltd?
The ROCE of Global Longlife Hospital and Research Ltd is 13.7 %.
What is the ROE of Global Longlife Hospital and Research Ltd?
The ROE of Global Longlife Hospital and Research Ltd is 17.7 %.
What is the Face Value of Global Longlife Hospital and Research Ltd?
The Face Value of Global Longlife Hospital and Research Ltd is 10.0.